CARsgen Therapeutics, a global leader in developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, announced its first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers has entered into phase-I clinical trial and starts patients recruitment at Changhai Hospital of Shanghai, a renowned hospital of global reputation for expertise on gastroesophageal and related cancer.
http://www.pharmabiz.com/NewsDetails.aspx?aid=103674&sid=2
CARsgen begins phase-I trial of its anti-Claudin18.2-CAR-T cell therapy for gastric & pancreatic cancers